LIPS-A: Lung Injury Prevention Study With Aspirin
This is a multi-center, phase, phase II double-blind, placebo-controled, randomized trial of aspirin for the prevention of acute lung injury in patients identified as at risk for acute lung injury.
- drug : Lactose powder
- drug : Aspirin
Phase: Phase 2
Ages Eligible For Study:
- Adult patients (age > 18) admitted to the hospital through the emergency department (ED) - At high risk of developing ALI (Lung Injury Prediction Score-LIPS greater than or equal to 4)